Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 1
1974 1
1982 1
1983 2
1987 1
1990 1
1993 1
1995 1
1996 3
1997 1
1998 1
1999 2
2001 1
2002 1
2003 2
2006 1
2007 3
2008 3
2009 3
2010 1
2012 1
2013 2
2014 6
2015 1
2016 2
2017 2
2018 6
2019 6
2020 7
2021 7
2022 5
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), and fatigue (51.9% and 54.5%). Severe and serious adverse events were …
The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45 …
Cutaneous manifestations associated with immune checkpoint inhibitors.
Watanabe T, Yamaguchi Y. Watanabe T, et al. Front Immunol. 2023 Feb 20;14:1071983. doi: 10.3389/fimmu.2023.1071983. eCollection 2023. Front Immunol. 2023. PMID: 36891313 Free PMC article. Review.
Skin manifestations are characterized by a wide range of phenotypes, including maculopapular rash, psoriasiform eruption, lichen planus-like eruption, pruritus, vitiligo-like depigmentation, bullous diseases, alopecia, and Stevens-Johnson syndrome/toxic epidermal ne …
Skin manifestations are characterized by a wide range of phenotypes, including maculopapular rash, psoriasiform eruption, lichen planus-like …
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Muntyanu A, et al. J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76. doi: 10.1177/1203475420943260. Epub 2020 Aug 3. J Cutan Med Surg. 2021. PMID: 32746624 Review.
For instance, maculopapular eruptions rarely affect <30% BSA and can often be managed conservatively with skin-directed therapies, while Stevens-Johnson syndrome (SJS) affecting even 5% BSA should be managed aggressively and the immunotherapy should be discontinued at o …
For instance, maculopapular eruptions rarely affect <30% BSA and can often be managed conservatively with skin-directed therapies, while …
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Tolaney SM, et al. J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2. J Clin Oncol. 2021. PMID: 34077270 Clinical Trial.
Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. ...
Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better w …
Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology.
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ. Hong JJ, et al. Dermatol Online J. 2021 Nov 15;27(11). doi: 10.5070/D3271156085. Dermatol Online J. 2021. PMID: 35130397 Review.
IL-12 and IL-23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in skin disorders....
IL-12 and IL-23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses …
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.
Pach J, Leventhal JS. Pach J, et al. Crit Rev Immunol. 2022;42(4):1-20. doi: 10.1615/CritRevImmunol.2023046895. Crit Rev Immunol. 2022. PMID: 37022356 Review.
Examples include pruritus and maculopapular eruption most commonly, psoriasis and bullous dermatoses less commonly, and, rarely, severe, life-threatening eruptions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Many of these are autoimmune in nature, and t …
Examples include pruritus and maculopapular eruption most commonly, psoriasis and bullous dermatoses less commonly, and, rarely, severe, lif …
Imatinib mesylate-induced lichenoid drug eruption.
Penn EH, Chung HJ, Keller M. Penn EH, et al. Cutis. 2017 Mar;99(3):189-192. Cutis. 2017. PMID: 28398413 Review.
Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash. Other less common manifestations include exfoliative dermatitis, nail disorders, psoriasis, folliculitis, hypotrichosis …
Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and ph …
Histopathology of Cutaneous Inflammatory Disorders in Children.
Hsi AC, Rosman IS. Hsi AC, et al. Pediatr Dev Pathol. 2018 Mar-Apr;21(2):115-149. doi: 10.1177/1093526617748781. Pediatr Dev Pathol. 2018. PMID: 29607753 Review.
Hypersensitivity reactions can show either epidermal or mostly dermal changes depending on whether the exposure of the exogenous allergen occurs through an external or internal route, respectively. Exceptions include erythema multiforme and Stevens-Johnson syndrome/toxic e …
Hypersensitivity reactions can show either epidermal or mostly dermal changes depending on whether the exposure of the exogenous allergen oc …
Case report: Alpelisib-induced Stevens-Johnson syndrome.
Kurian CJ, Desai A, Rafferty W, Abou Hussein AK. Kurian CJ, et al. Front Oncol. 2022 Sep 28;12:954027. doi: 10.3389/fonc.2022.954027. eCollection 2022. Front Oncol. 2022. PMID: 36249040 Free PMC article.
BACKGROUND: Alpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. It has been associated with alopecia and rash, but there are no documented cases of Stevens-Johnson Syndrome (SJS) associated …
BACKGROUND: Alpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. …
76 results